Morgan Stanley Cuts Johnson & Johnson (NYSE:JNJ) Price Target to $167.00

Johnson & Johnson (NYSE:JNJ) had its price objective decreased by stock analysts at Morgan Stanley from $168.00 to $167.00 in a report issued on Wednesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 15.36% from the stock’s previous close.

Several other research firms also recently weighed in on JNJ. Royal Bank of Canada decreased their price target on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday. Bank of America dropped their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Raymond James lifted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $176.21.

Johnson & Johnson Trading Up 0.2 %

NYSE:JNJ opened at $144.77 on Wednesday. The company has a 50 day simple moving average of $156.54 and a two-hundred day simple moving average of $155.74. The company has a market cap of $348.86 billion, a PE ratio of 9.03, a price-to-earnings-growth ratio of 2.40 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12 month low of $143.39 and a 12 month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The company had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the prior year, the company earned $2.68 earnings per share. Johnson & Johnson’s revenue was up 2.3% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Insider Buying and Selling

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Skyline Advisors Inc. boosted its stake in shares of Johnson & Johnson by 3.5% during the first quarter. Skyline Advisors Inc. now owns 2,478 shares of the company’s stock valued at $392,000 after purchasing an additional 83 shares in the last quarter. Aviance Capital Partners LLC boosted its position in Johnson & Johnson by 63.3% during the 1st quarter. Aviance Capital Partners LLC now owns 37,818 shares of the company’s stock valued at $5,982,000 after acquiring an additional 14,663 shares in the last quarter. Mirador Capital Partners LP increased its holdings in shares of Johnson & Johnson by 4.2% in the 1st quarter. Mirador Capital Partners LP now owns 20,508 shares of the company’s stock valued at $3,244,000 after acquiring an additional 833 shares during the period. SteelPeak Wealth LLC raised its position in shares of Johnson & Johnson by 11.5% in the 1st quarter. SteelPeak Wealth LLC now owns 58,409 shares of the company’s stock worth $9,240,000 after acquiring an additional 6,045 shares in the last quarter. Finally, Breakwater Capital Group grew its stake in Johnson & Johnson by 13.0% in the first quarter. Breakwater Capital Group now owns 7,818 shares of the company’s stock valued at $1,237,000 after purchasing an additional 899 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.